{"id":"9a3bd8f6-f19d-525d-ab73-b17be6c7b04b","stable_key":"7484635e-cc8f-5cd6-a978-6dc5775a7db5:berberine-human-cyp-2c19-null","predicate":"no_significant_change_in","statement":"No statistically significant change in omeprazole probe pharmacokinetics was found after berberine.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"fcbfca67-8105-5f82-9f5e-6a581be05759","mechanism_event_label":"The CYP2C19 probe result was also negative under these conditions.","subject":{"id":"7bbe0633-b2f1-510f-adc0-3c4d0ddad05d","slug":"berberine","display_name":"Berberine","entity_type_key":"small_molecule"},"object":{"id":"13e1d51d-97b7-5c17-800d-899ecd25c7c2","slug":"cyp2c19-phenotypic-activity","display_name":"CYP2C19 activity measured by probe-drug phenotyping","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"fcbfca67-8105-5f82-9f5e-6a581be05759","stable_key":"7484635e-cc8f-5cd6-a978-6dc5775a7db5:berberine-human-cyp-2c19-null-event","event_type":"observed_intervention","label":"The CYP2C19 probe result was also negative under these conditions.","description":"No statistically significant change in omeprazole probe pharmacokinetics was found after berberine.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"cc080b54-fd5d-5cc0-930e-2cb86c116c68","slug":"cyp2c19","display_name":"Human cytochrome P450 2C19","entity_type_key":"protein"},"role":"phenotyped_enzyme","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"a9941a82-a3e4-5b0a-9a98-484451d914e0","slug":"omeprazole","display_name":"Omeprazole","entity_type_key":"small_molecule"},"role":"probe_drug","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"7bbe0633-b2f1-510f-adc0-3c4d0ddad05d","slug":"berberine","display_name":"Berberine","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"13e1d51d-97b7-5c17-800d-899ecd25c7c2","slug":"cyp2c19-phenotypic-activity","display_name":"CYP2C19 activity measured by probe-drug phenotyping","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/berberine-research/21870106.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"12e465c3c0a8ce995697a6fb9bf77c079e38b413e82c8b4f2a82e45a3dbf8ae5\", \"start_char\": 0, \"end_char\": 1817, \"text_sha256\": \"12e465c3c0a8ce995697a6fb9bf77c079e38b413e82c8b4f2a82e45a3dbf8ae5\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Two-phase randomized crossover enzyme-phenotyping study","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Berberine 300 mg three times daily for 14 days versus placebo","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Small short-term study. Probe metabolic ratios are not percentage inhibition of every substrate. No universal dose-adjustment rule; no statistically significant effect is not equivalence.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Berberine research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"berberine","display_name":"Berberine","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"Healthy human male volunteers; 17 completed","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The CYP2C19 probe result was also negative under these conditions.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[berberine-p21870106] Repeated administration of berberine inhibits cytochromes P450 in humans. (2012). https://pubmed.ncbi.nlm.nih.gov/21870106/ DOI: 10.1007/s00228-011-1108-2","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Oral probe pharmacokinetics and urinary metabolite ratios","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"53595166-bd76-5d02-b1b1-6c22d99fa63d","evidence_kind":"source_excerpt","locator":"Lines 688-699","start_line":688,"end_line":699,"excerpt":"### berberine-human-cyp-2c19-null\nNo statistically significant change in omeprazole probe pharmacokinetics was found after berberine.\nCondition category: normal\nnutrient_topic: Berberine research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: The CYP2C19 probe result was also negative under these conditions.\norganism: Healthy human male volunteers; 17 completed\ntissue_or_cell_type: Oral probe pharmacokinetics and urinary metabolite ratios\nexperimental_model: Two-phase randomized crossover enzyme-phenotyping study\nlimitations: Small short-term study. Probe metabolic ratios are not percentage inhibition of every substrate. No universal dose-adjustment rule; no statistically significant effect is not equivalence.\nexposure: Berberine 300 mg three times daily for 14 days versus placebo\nevidence_span: {\"source_cache\": \"artifacts/berberine-research/21870106.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"12e465c3c0a8ce995697a6fb9bf77c079e38b413e82c8b4f2a82e45a3dbf8ae5\", \"start_char\": 0, \"end_char\": 1817, \"text_sha256\": \"12e465c3c0a8ce995697a6fb9bf77c079e38b413e82c8b4f2a82e45a3dbf8ae5\"}\n[berberine-p21870106] Repeated administration of berberine inhibits cytochromes P450 in humans. (2012). https://pubmed.ncbi.nlm.nih.gov/21870106/ DOI: 10.1007/s00228-011-1108-2","model_system":"Two-phase randomized crossover enzyme-phenotyping study","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [berberine-p21870106] Repeated administration of berberine inhibits cytochromes P450 in humans. (2012). https://pubmed.ncbi.nlm.nih.gov/21870106/ DOI: 10.1007/s00228-011-1108-2","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"9bb61e1d-e5cf-5b05-a9ca-409291f7a313","stable_key":"import-7484635e-cc8f-5cd6-a978-6dc5775a7db5","title":"Berberine: metabolism, nutrient connections and drug interactions (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"2f376a035ae79c93e62e2ea4a8d5385643bf16553f108d12b6a80c89e6d41f4c","revision_id":"2a099429-1c4a-55be-aa2c-0565d08bda80","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}